New Discoveries in Cancer Treatment: Nilotinib’s Potential

Understanding Hedgehog-Dependent Medulloblastoma

Hedgehog-dependent medulloblastoma is a severe form of brain cancer, accounting for approximately one-third of all childhood brain cancers. The Hedgehog (Hh) molecular signaling pathway, particularly its component Smoothened (SMO), plays a crucial role in normal embryonic development. However, abnormal activation of this pathway and excessive SMO production are linked to various cancers, including medulloblastoma. This pathway is also significant in sustaining cancer stem cells, and its dysregulation contributes to tumor resistance against chemotherapy and radiation therapy, leading to relapses.

Current Treatment Limitations

Current therapies for Hh-dependent cancers primarily target the SMO component of the Hh pathway. Unfortunately, SMO-specific antagonists often yield limited effectiveness, with only a small percentage of Hh-Medulloblastoma patients responding favorably to these drugs. The high rates of resistance and relapse necessitate research into treatments with multiple targeting mechanisms to effectively combat specific cancer subtypes.

Breakthrough Research on Nilotinib

New Mechanisms of Action

Recent findings published in PLOS ONE by a team of researchers in the United States reveal that nilotinib, a drug traditionally used for leukemia, exhibits activity against SMOs in the Hh pathway—a mechanism previously unidentified. The researchers identified approved drugs with proven anti-cancer properties that shared characteristics with existing SMO antagonists. Utilizing three-dimensional docking models, they screened these drugs for their potential to bind to SMOs, concluding that nilotinib emerged as a leading candidate with significant binding potential.

Nilotinib’s Effects on Tumor Growth

Further investigations involved administering nilotinib to mice injected with human medulloblastoma tumors. The results indicated that nilotinib treatment led to reduced tumor growth without any observed tumor resistance. Notably, nilotinib demonstrated anti-SMO activity alongside its established anti-cancer properties, suggesting its multi-target action could surpass the efficacy of current SMO antagonists in treating Hh-dependent tumors.

Future Directions for Nilotinib in Cancer Therapy

Potential Applications in Hh-Dependent Cancers

This discovery underscores nilotinib’s potential role in treating specific Hh-dependent cancers, particularly Hh-medulloblastoma. Although the drug has not yet been specifically studied in this context, ongoing research is exploring its applications in brain cancers. As an FDA-approved medication with a well-established efficacy and safety profile, nilotinib is generally well tolerated for long-term use. Given these promising findings, the researchers advocate for nilotinib as a potential candidate for treating certain cancers, either as a standalone treatment or in conjunction with other anti-cancer therapies.

References

Chahal, K. K., Li, J., Kufareva, I., Parle, M., Durden, D. L., Wechsler-Reya, R. J., … Abagyan, R. (2019). Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. Plos One, 14(9). doi: 10.1371/journal.pone.0214901

Leukemia drug shows promise for treating a childhood brain cancer. (2019, September 20). Retrieved from https://www.eurekalert.org/pub_releases/2019-09/uoc–lds092019.php

Image by Belova59 from Pixabay.